- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04052516
A Phase 2b Study of Icosabutate in Fatty Liver Disease (ICONA)
December 17, 2021 updated by: NorthSea Therapeutics B.V.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of NST-4016 in Patients With Nonalcoholic Steatohepatitis (NASH)
A Phase 2b study to evaluate the efficacy of different doses of NST-4016 on the resolution of NASH without worsening of fibrosis
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a 62 week (including screening and follow-up), multicenter, randomized, double blind, placebo-controlled, parallel group study in male and female patients with a histological diagnosis of NASH.
The study includes a screening period, double blind treatment period, and post-treatment follow up
Study Type
Interventional
Enrollment (Actual)
280
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
San Juan, Puerto Rico, 00927-4807
- Fundacion de Investigacion (FDI)
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- Central ResearchAssociates Inc.
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- Arizona Liver Health
-
Glendale, Arizona, United States, 85306
- Arizona Liver Health - Glendale
-
Tucson, Arizona, United States, 85712
- Adobe Clinical Research, LLC
-
Tucson, Arizona, United States, 85711
- Arizona Liver Health
-
-
Arkansas
-
North Little Rock, Arkansas, United States, 72117
- Arkansas Gastroenterology - North Little Rock
-
-
California
-
Fresno, California, United States, 93720
- Fresno Clinical Research Center
-
Huntington Park, California, United States, 90255
- National Research Institute - Huntington Park
-
Los Angeles, California, United States, 90057
- National Research Institute - Wilshire
-
Panorama City, California, United States, 91402
- National Research Institute - Panorama
-
Poway, California, United States, 92064
- Alliance Clinical Research
-
Santa Ana, California, United States, 92704
- National Research Institute - Santa Ana
-
-
Colorado
-
Englewood, Colorado, United States, 80113
- South Denver Gastroenterology
-
-
Florida
-
Boca Raton, Florida, United States, 33434
- Excel Medical Clinical Trials, LLC
-
Ocoee, Florida, United States, 34761
- Sensible Healthcare LLC
-
Sarasota, Florida, United States, 34240
- Covenant Research LLC
-
-
Georgia
-
Marietta, Georgia, United States, 30060
- Gastrointestinal Specialists of Georgia PC
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Texas Digestive Disease Consultants
-
Marrero, Louisiana, United States, 70072
- Tandem Clinical Research
-
-
Mississippi
-
Flowood, Mississippi, United States, 39232
- Gastrointestinal Associates, PA
-
Jackson, Mississippi, United States, 39216
- Southern Therapy and Advanced Research LLC
-
-
Missouri
-
Kansas City, Missouri, United States, 64131
- Kansas City Research Institute
-
-
North Carolina
-
Fayetteville, North Carolina, United States, 28304
- Cumberland Research Associates, LLC
-
-
Ohio
-
Columbus, Ohio, United States, 43213
- Aventiv Research, Inc.
-
-
Tennessee
-
Clarksville, Tennessee, United States, 37040
- Premier Research
-
Germantown, Tennessee, United States, 38138
- Gastro One
-
-
Texas
-
Austin, Texas, United States, 78746
- Pinnacle Clinical Research
-
Dallas, Texas, United States, 75246
- Texas Digestive Disease Consultants
-
Edinburg, Texas, United States, 78539
- South Texas Research Institute
-
Houston, Texas, United States, 77030
- Liver Associates of Texas
-
McAllen, Texas, United States, 78504
- Doctors Hospital at Renaissance, LLC
-
San Antonio, Texas, United States, 78234
- Brooke Army Medical Center
-
San Antonio, Texas, United States, 78229
- Pinnacle Clinical Research
-
San Antonio, Texas, United States, 78209
- Quality Research Inc
-
San Antonio, Texas, United States, 78215
- American Research Corporation
-
Webster, Texas, United States, 77598
- Texas Digestive Disease Consultants - Webster
-
-
Virginia
-
Richmond, Virginia, United States, 23249
- Hunter Holmes McGuire VA Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provides signed written informed consent and agrees to comply with the study protocol.
- Is a male or female aged 18 to 75 years, inclusive.
- Has a histological diagnosis of NASH prior to study entry
- Has (NAS) greater than or equal to 4, with a score of at least 1 in each component (steatosis, lobular inflammation, and ballooning),
- Has a fibrosis score F1 to F3, inclusive (F1 capped at 30%),
- Has a Proton Density Fat Fraction (PDFF) greater than or equal to 10% on MRI at screening
Exclusion Criteria:
- Has a known history of alcohol abuse or daily heavy alcohol consumption
- Has had bariatric surgery within the past 5 years
- Has significant systemic or major illnesses other than liver disease
- Has a recent (within 6 months) history of cardiac dysrhythmias and/or cardiovascular disease
- Has uncontrolled arterial hypertension
- Positive for Hep B, Hepatitis C Virus (HCV) or HCV Polymerase Chain Reaction (PCR)
- Has type 1 diabetes mellitus
- Has diabetic ketoacidosis
- Has a history of liver decompensation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo oral capsules taken one daily for 52 weeks
|
Matching placebo oral capsule
|
Experimental: Icosabutate 300mg
Icosabutate 300mg oral capsule taken once daily for 52 weeks
|
Icosabutate oral capsule once daily
Other Names:
|
Experimental: Icosabutate 600mg
Icosabutate 600mg oral capsules taken once daily for 52 weeks
|
Icosabutate oral capsule once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
percentage of patients with resolution of NASH, defined as disappearance of ballooning (score = 0) with lobular inflammation score 0 or 1, with no worsening of fibrosis.
Time Frame: 52 weeks
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in Nonalcoholic fatty liver disease (NAFLD) activity score (NAS)
Time Frame: 52 weeks
|
A histological scoring system that assesses a liver biopsy and gives scores for steatosis (0-3), lobular inflammation (0-3), and hepatocyte ballooning (0-2) giving a total score of (0-8).
The higher the score the more severe the disease
|
52 weeks
|
Changes in individual histological scores for steatosis, ballooning, inflammation, and fibrosis from baseline
Time Frame: 52 weeks
|
Changes in scores for the individual component parts of the Nonalcoholic fatty liver disease (NAFLD) activity score (NAS) as judged by a pathologist examining sections from a liver biopsy; steatosis (range 0-3), lobular inflammation (range 0-3), and hepatocyte ballooning (range 0-2) In all cases a higher number denotes more severe disease activity
|
52 weeks
|
Changes in the liver enzymes Aspartate Aminotransferase (AST)U/L, Alanine Aminotransferase ( ALT)U/L and Gamma Glutamyl Transferase (GGT) U/L from baseline
Time Frame: 52 weeks
|
52 weeks
|
|
Change in bilirubin mg/dL from baseline
Time Frame: 52 weeks
|
52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 17, 2019
Primary Completion (Anticipated)
October 31, 2022
Study Completion (Anticipated)
January 30, 2023
Study Registration Dates
First Submitted
August 7, 2019
First Submitted That Met QC Criteria
August 8, 2019
First Posted (Actual)
August 9, 2019
Study Record Updates
Last Update Posted (Actual)
December 20, 2021
Last Update Submitted That Met QC Criteria
December 17, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NST-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Alcoholic Steatohepatitis (NASH)
-
Corcept TherapeuticsRecruitingNon-alcoholic Steatohepatitis (NASH)United States
-
Novartis PharmaceuticalsTerminatedNon-alcoholic Steatohepatitis (NASH)Belgium, Germany, Taiwan, Austria, United States, Spain, Korea, Republic of, Argentina, Australia, Italy, Japan, Singapore, Netherlands, Slovakia, France, Canada, India
-
Immuron Ltd.CompletedNon-alcoholic Steatohepatitis (NASH)United States, Australia, Israel
-
EccogeneRecruiting
-
Guangdong Raynovent Biotech Co., LtdCompletedNon-Alcoholic Steatohepatitis (NASH)China
-
Novartis PharmaceuticalsTerminatedNon-alcoholic Steatohepatitis NASHUnited Kingdom, United States, Australia, New Zealand, Switzerland, Jordan, Georgia, Puerto Rico
-
Hoffmann-La RocheCompletedNon-Alcoholic Steatohepatitis (NASH)France
-
University of ZurichCompletedNon-alcoholic Steatohepatitis (NASH)Switzerland
-
Haisco Pharmaceutical Group Co., Ltd.RecruitingNon-Alcoholic Steatohepatitis (NASH)China
-
AstraZenecaActive, not recruitingNon-alcoholic Steatohepatitis (NASH)United States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States